Search research articles
Contact Us
Filters
Showing results (31-40 of 499) with videos related to
Page
of 50
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2015
Reply to S. Debska-Szmich et al
Eric Van Cutsem, Frank Beier, Fortunato Ciardiello
Seminars in Oncology
|
February 24, 2005
Oral capecitabine: bridging the Atlantic divide in colon cancer treatment
Eric Van Cutsem, Chris Verslype, Sabine Tejpar
BJS Open
|
December 22, 2022
Health-related quality of life in rectal cancer: a topic more relevant now than ever
Albert M Wolthuis, André D'Hoore, Eric Van Cutsem
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2008
Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Jim Cassidy, Hans-Joachim Schmoll, Eric Van Cutsem
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2007
Lessons learned in the management of advanced pancreatic cancer
Eric Van Cutsem, Chris Verslype, Patrick A Grusenmeyer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2019
Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker <i>Post Hoc</i> Analysis of the VELOUR Trial
Eric Van Cutsem, Caroline Paccard, Marielle Chiron, et al.
European Journal of Clinical Pharmacology
|
July 25, 2014
Treatment-related mortality with aflibercept in cancer patients
Josep Tabernero, Simon Hitier, Eric Derobert, et al.
Clinical Colorectal Cancer
|
April 30, 2017
Predictive Value of Early Tumor Shrinkage and Density Reduction of Lung Metastases in Patients With Metastatic Colorectal Cancer Treated With Regorafenib
Hannes Vanwynsberghe, Xander Verbeke, Johan Coolen, et al.
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society
|
September 3, 2004
Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda)
Hilde Marsé, Eric Van Cutsem, Axel Grothey, et al.
Targeted Oncology
|
November 25, 2011
Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents
Andreia Costa, Sabine Tejpar, Hans Prenen, et al.
Page
of 50
Search research articles
Search
Showing results (31-40 of 499) with videos related to
Sort By:
Page
of 50
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2015
Reply to S. Debska-Szmich et al
Eric Van Cutsem, Frank Beier, Fortunato Ciardiello
Seminars in Oncology
|
February 24, 2005
Oral capecitabine: bridging the Atlantic divide in colon cancer treatment
Eric Van Cutsem, Chris Verslype, Sabine Tejpar
BJS Open
|
December 22, 2022
Health-related quality of life in rectal cancer: a topic more relevant now than ever
Albert M Wolthuis, André D'Hoore, Eric Van Cutsem
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2008
Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Jim Cassidy, Hans-Joachim Schmoll, Eric Van Cutsem
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2007
Lessons learned in the management of advanced pancreatic cancer
Eric Van Cutsem, Chris Verslype, Patrick A Grusenmeyer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2019
Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker <i>Post Hoc</i> Analysis of the VELOUR Trial
Eric Van Cutsem, Caroline Paccard, Marielle Chiron, et al.
European Journal of Clinical Pharmacology
|
July 25, 2014
Treatment-related mortality with aflibercept in cancer patients
Josep Tabernero, Simon Hitier, Eric Derobert, et al.
Clinical Colorectal Cancer
|
April 30, 2017
Predictive Value of Early Tumor Shrinkage and Density Reduction of Lung Metastases in Patients With Metastatic Colorectal Cancer Treated With Regorafenib
Hannes Vanwynsberghe, Xander Verbeke, Johan Coolen, et al.
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society
|
September 3, 2004
Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda)
Hilde Marsé, Eric Van Cutsem, Axel Grothey, et al.
Targeted Oncology
|
November 25, 2011
Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents
Andreia Costa, Sabine Tejpar, Hans Prenen, et al.
Page
of 50